Family History of Liver Cancer and Hepatocellular Carinoma
Sixty-Five Gene-Based Risk Score Classifier Predicts Overall Survival in Hepatocellular Carcinoma
Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/IIhepatocellular carcinoma.
Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage.
Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma.
Gene pathway analysis of hepatocellular carcinoma genomic expression datasets.
Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria.
Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.
Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials.
Clinical and Prognostic Implications of Plasma Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma
The HOX gene network in hepatocellular carcinoma.
Locoregional Therapy-Induced Tumor Necrosis as a Predictor of Recurrence after Liver Transplant in Patients with Hepatocellular Carcinoma.
The Missing Link between Obesity and Hepatocellular Carcinoma:IL-6-Mediated STAT-3 Activation as a Key Player in Hepatocarcinogenesis.
JAK-STAT signaling in hepatic fibrosis.
Genomic instability caused by hepatitis B virus: into the hepatoma inferno.
Radiotherapy Plus Transarterial Chemoembolization for Hepatocellular Carcinoma Invading the Portal Vein: Long-Term Patient Outcomes.
Survival after (90) Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation.
c-MET represents a potential therapeutic target for personalized treatment in Hepatocellular carcinoma.
Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan cirteria.
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers.
Detection of small intrahepatic metastases of hepatocellular carcinoma using diffusion-weighted imaging: comparison with conventional dynamic MRI.
Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Adjuvant Chemolipiodolization Reduces Early Recurrence Derived from Intrahepatic Metastasis of Hepatocellular Carcinoma After Hepatectomy.
Molecular classification of hepatocellular carcinoma anno 2011.
Saffron: A potential target for a novel anti-cancer drug against hepatocellular carcinoma.
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Patient Involvement in Healthcare is Associated With Higher Rates of Surveillance for Hepatocellular Carcinoma.
Management of chronic hepatitis B.
Gene Pathway Analysis of Hepatocellular Carcinoma Genomic Expression Datasets.
Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma.
Tissue biomarkers as predictors of outcome and selection of transplant candidates in hepatocellular carcinoma.
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Portal Venous Invasion: The Single Most Independent Risk Factor for Immediate Postoperative Recurrence of Hepatocellular Carcinoma.
Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma.
Significance of Tumor Necrosis for Outcome of Patients with Hepatocellular Carcinoma Receiving Locoregional Therapy Prior to Liver Transplantation.
Translating Basic Biology for Therapeutic Targeting of Hepatocellular Carcinoma.
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma: A randomized placebo-controlled, double-blind phase II/III study.
Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma.
Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.
Chemoembolization for Hepatocellular Carcinoma: Multivariate Analysis of Predicting Factors for Tumor Response and Survival in a 362-patient Cohort.
Expression and role of SIRT1 in hepatocellular carcinoma.
Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma.
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoemolisation.
[Expression and clinical significance of VEGF in tissue of primary hepatocellular carcinoma].
Molecular pathology of hepatic neoplasms: classification and clinical significance.
Gemcitabine and Docetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial.
Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma.
Therapeutic potential of targeting Glypican-3 in Hepatocellular Carcinoma.
New Molecular Mechanism of Liver Cancer.
High Aromatase Activity and Overexpression of Epidermal Growth Factor Receptor in Fibrolamellar Hepatocellular Carcinoma in a Child.
Growth of hepatocellular carcinoma in the regenerating liver.
Metabolic syndrome increases the risk of primary liver cancer in the United States: A population-based control study.
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Genetics of hepatobiliary carcinogenesis.
Integrated Analysis of Prognostic Gene Expression Profiles from Hepatitis B Virus-Positive Hepatocellular Carcinoma and Adjacent Liver Tissue.
Long-term survival after transarterial chemoembolization of hepatocellular carcinoma.
Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma.
Microvascular Invasion is a Better Predictor of Tumor Recurrence and Overall Survival After Surgical Resection for Hepatocellular Carcinoma Compared to the Milan Criteria.
Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer.
Preoperative portal vein embolization (PVE) for patients with hepatocellular carcinoma can improve resectability and may improve disease-free survival.
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma.
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Epigenetic mechanisms in hepatocellular carcinoma: How environmental factors influence the epigenome.
Monitoring Response to Antiangiogenic Treatment and Predicting Outcomes in Advanced Hepatocellular Carcinoma Using Image Biomarkers, CT Perfusion, Tumor Density, and Tumor Size (RECIST).
Immunosuppression and hepatocellular carcinoma.
Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma witin the Milan criteria: A propensity score analyis.
Hepatocellular carcinoma and gene profiling: Back from perspective to reality.
Hepatocellular carcinomas can develop in simple fatty livers in the setting of oxidative stress.
The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature.
Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion.
Gene expression signature of the gross morphology in hepatocellular carcinoma.
Coffee and the liver: a potential treatment for liver disease?
Radiofrequency ablation leads to excellent local tumor control and durable longterm survival in specific subsets of early stage HCC patients confirming to the Milan criteria.
Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma.
Liver transplantation: from guidelines to randomized controlled trials.
Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity.
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma.
Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma.
Last Updated on 5/23/2012 1:31:42 PM
"Join us in the quest to cure bile duct, gallbladder andliver cancers."
This site complies with the HONcode standard for trustworthy health information:
Legal Disclaimer | Privacy | All Rights Reserved. © 2011 CanLiv, The Hepatobiliary Cancers Foundation
CanLiv The Hepatobiliary Cancers Foundation | 164 Market Street Suite 129 | Charleston, SC | 29401
Site Created June 2011
Board Member Login | Consortium Login
Web Design by BlueKey in Charleston, SC